Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for correction of anemia in non-dialysis chronic kidney disease
2006-001434-41Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in Uraemic Anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Roche. Primary endpoints: Hemoglobin response rate and Change in average hemoglobin concentration. Started Sep 2006; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
Uraemic Anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-001434-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001434-41.